Currently out of the existing stock ratings of Catherine Novack, 12 are a BUY (85.71%), 2 are a HOLD (14.29%).

Catherine Novack

Work Performance Price Targets & Ratings Chart

Analyst Catherine Novack, currently employed at JONESTRADING, carries an average stock price target met ratio of 31.25% that have a potential upside of 53.11% achieved within 105 days.

Catherine Novack’s has documented 27 price targets and ratings displayed on 8 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CAPR, Capricor Therapeutics at 24-Jun-2025.

Wall Street Analyst Catherine Novack

Analyst best performing recommendations are on WVE (WAVE LIFE SCIENCES LTD).
The best stock recommendation documented was for WVE (WAVE LIFE SCIENCES LTD) at 8/9/2024. The price target of $12 was fulfilled within 68 days with a profit of $6.59 (121.81%) receiving and performance score of 17.91.

Average potential price target upside

DARE Dare Bioscience KZR Kezar Life Sciences ALDX Aldeyra The FEMY Femasys WVE Wave Life Sciences Ltd CAPR Capricor Therapeutics LRMR Larimar Therapeutics RGLS Regulus Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$8

$5.88 (277.36%)

1 months 8 days ago
(03-Sep-2025)

1/2 (50%)

$5.87 (275.59%)

660

Buy

$12

$9.88 (466.04%)

$12

6 months 11 days ago
(31-Mar-2025)

0/5 (0%)

$9.1 (313.79%)

Buy

$13

$10.88 (513.21%)

1 years 1 months 26 days ago
(15-Aug-2024)

0/1 (0%)

$9.43 (264.15%)

Buy

$3

$0.09 (3.09%)

1 years 4 months 27 days ago
(15-May-2024)

2/2 (100%)

$-1.32 (-30.56%)

135

Buy

$2

$-0.12 (-5.66%)

2 years 1 months 12 days ago
(29-Aug-2023)

1/1 (100%)

$-6.52 (-76.53%)

709

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Catherine Novack is most bullish on?

Potential upside of $21.91 has been obtained for CAPR (CAPRICOR THERAPEUTICS)

Which stock is Catherine Novack is most reserved on?

Potential downside of -$1.16 has been obtained for RGLS (REGULUS THERAPEUTICS)

What Year was the first public recommendation made by Catherine Novack?

On 2022

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?